Excerpts from SooChow CSSD Capital Markets (Asia) report

Analyst: Cheah Zhuo En

A Giant Leap into China

CLGL made an indicative non-binding proposal for the proposed combination with Global Cord Blood Corporation (GCB) (CO US) via a share swap arrangement.

Cordlife

Share price: 
46.5 c

Target: 
65 c

CLGL intends to fund the transaction by raising S$1.25bn via issuing 2,497.9m new shares at S$0.50/shr.

We expect ~30.8% accretion to FY20E EPS should the deal complete by end-2019.

Maintain BUY with TP $0.65/shr, pending shareholder approval and more details on the deal.



TanPohLan arCordlife CEO Tan Poh Lan: Has 30 years of experience in the healthcare sector. Previously, she was the CEO of Parkway East Hospital and Gleneagles Hospital in Singapore, Vinmec International Hospital in Hanoi, Vietnam and Fortis Healthcare Singapore. In congruence with CLGL’s M&A driven growth DNA; albeit at a larger scale: While still at a very preliminary stage, we see the deal strongly positive to CLGL.

Upon successful completion, we expect CLGL to officially be largest cord blood bank in the world, noting that GCB is currently the no.1 player in Mainland China.

More importantly, we expect the deal to be highly accretive to CLGL EPS given that

1) the offer price implies 21.4x P/E for GCB (vs. CLGL swapping at 33.7x FY19E P/E); and

2) GCB is more profitable than CLGL (GCB NPM: 29.1% vs. CLGL NPM: 5.1%), with LTM net income of S$58.0m, which is ~15x that of CLGL FY19E net income of S$3.8m.


GCB is the market leader in China and a quality target: GCB has a very similar, cash-generative business model as CLGL, but at a ~4x scale (in terms of revenues) as compared to CLGL given that it is the market leader in the largest market in the world.

As such, the target maintains a substantial net cash position of S$852m (~76% of market cap).

Based on simple extrapolation, we expect the net cash position of the enlarged entity to be ~S$895.7m (~65.0% of the implied market cap post-merger).

Maintain BUY: Given that the deal is still at the preliminary stage and subject to approval by CLGL (simple majority excluding Sanpower Group) and GCB (two-thirds of shareholders’ approval), we will review our investment thesis as more public information surface.

We maintain BUY TP $0.65/shr, noting that the current target price does not account for the impact of the deal.


Full report here


Share Prices

Counter NameLastChange
AEM Holdings3.2500.010
AusGroup0.026-
Avi-Tech Electronics0.4400.005
Best World Int.1.360-
CEI0.845-0.015
China Sunsine0.355-0.010
CNMC GoldMine0.260-0.005
CSE Global0.460-0.015
Food Empire0.530-
Golden Energy0.168-
GSS Energy0.0670.001
ISDN Holdings0.210-0.005
ISOTeam0.148-0.002
IX Biopharma0.2650.010
JB Foods0.6000.020
KSH Holdings0.340-
Medtecs Intl0.9350.065
Moya Asia0.0640.002
Nordic Group0.210-0.015
Oxley Holdings0.240-
Procurri0.290-0.010
REX International0.177-
Riverstone3.4600.200
Roxy-Pacific0.335-0.010
Sing Holdings0.360-
SingMedical0.265-
Straco Corp.0.480-0.040
Sunningdale Tech1.0400.030
Sunpower Group0.4850.015
The Trendlines0.109-
Tiong Seng0.160-0.002
Uni-Asia Group0.5450.005
Yangzijiang Shipbldg0.945-

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 744 guests and no members online